Jim Cramer Says Oncology Drug Franchises Helping Both Celgene and Bristol-Myers

Earnings reports from Celgene and Bristol-Myers show the importance of great science for pharma and biotech companies, according to Jim Cramer.
Author:
Publish date:

Earnings reports from Celgene  (CELG) - Get Report  and Bristol-Myers  (BMY) - Get Report  show the importance of great science for pharma and biotech companies, according to TheStreet's Jim Cramer. He noted that both companies have strong amazing oncology drug franchises. Cramer said Bristol-Myers should not have traded lower following its results.